A61K 38/2264
Obesity-gene products
Official title: {Obesity-gene products, e.g. leptin}
A61K38/2264 (Obesity-gene products) appears on 175 US grants and 298 published applications in this corpus.
Search patents in A61K- Granted patents
- 175
- Published applications
- 298
- Assignees
- 168
- Inventors
- 541
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 3 | 0 |
| 1999 | 6 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 4 | 7 |
| 2003 | 7 | 14 |
| 2004 | 3 | 9 |
| 2005 | 7 | 17 |
| 2006 | 9 | 16 |
| 2007 | 7 | 7 |
| 2008 | 8 | 10 |
| 2009 | 1 | 16 |
| 2010 | 9 | 10 |
| 2011 | 8 | 18 |
| 2012 | 5 | 6 |
| 2013 | 7 | 21 |
| 2014 | 6 | 13 |
| 2015 | 6 | 14 |
| 2016 | 7 | 21 |
| 2017 | 7 | 9 |
| 2018 | 10 | 17 |
| 2019 | 14 | 18 |
| 2020 | 11 | 11 |
| 2021 | 9 | 10 |
| 2022 | 5 | 6 |
| 2023 | 4 | 7 |
| 2024 | 2 | 4 |
| 2025 | 4 | 11 |
| 2026 | 2 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating anorexia nervosa and related conditions by administering a leptin receptor agonist9 Jun 2026US 12,651,658 B2UniversitäT Duisburg-Essen
- Methods for improving leptin sensitivity for the treatment of obesity and diabetes24 Mar 2026US 12,582,702 B2University of Massachusetts
- Method of manufacturing diabetic foot patient-specific dermal regeneration sheet and diabetic foot patient-specific dermal regeneration sheet manufactured using the same11 Nov 2025US 12,465,622 B2Rokit Healthcare Inc.
- Leptin compositions and methods of making and using the same to support weight loss and/or maintenance11 Nov 2025US 12,466,883 B1Lumen Bioscience, Inc.
- Fusokines involving cytokines with strongly reduced receptor binding affinities9 Sep 2025US 12,410,222 B2Centre Hospitalier Regional Universitaire De Montpellier
- Methods for Improving Leptin Sensitivity for the Treatment of Obesity and Diabetes3 Sep 2026US 2026/0256888 A1University of Massachusetts
- Itih5 for use in the treatment of obesity16 Jul 2026US 2026/0199430 A1
- Fusokines involving cytokines with strongly reduced receptor binding affinities18 Jun 2026US 2026/0167687 A1Centre Hospitalier Regional Universitaire De Montpellier
- Leptin compositions and methods of making and using the same to support weight loss and/or maintenance2 Apr 2026US 2026/0092108 A1Lumen Bioscience, Inc.
- Method of manufacturing diabetic foot patient-specific dermal regeneration sheet and diabetic foot patient-specific dermal regeneration sheet manufactured using the same12 Feb 2026US 2026/0041717 A1Rokit Healthcare Inc.
Most cited
By later US patents
- Derivatives of GLP-1 analogs248US 6,268,343 B1Novo Nordisk A/S · 2001
- Use of exendins for the reduction of food intake124US 6,956,026 B2Amylin Pharmaceuticals, Inc. · 2005
- Polypeptide compositions with improved stability111US 7,022,674 B2Eli Lilly and Company · 2006
- Pharmaceutical compositions containing exendins98US 7,297,761 B2Amylin Pharmaceuticals, Inc. · 2007
- Exendins, exendin agonists, and methods for their use86US 6,989,366 B2Amylin Pharmaceuticals, Inc. · 2006